Cat. No. | Product name | CAS No. |
DC8111 |
Idarubicin Hydrochloride
Featured
Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor. |
57852-57-0 |
DC9014 |
Ifosfamide
Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer. |
3778-73-2 |
DC12310 |
INH154
INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC50s of 200 nM and 120 nM for INH in Hela and MB468 cells. |
1587705-63-2 |
DC7641 |
INH6
Featured
INH6 is a potent Hec1 inhibitor, which specifically disrupts the Hec1/Nek2 interaction and causes chromosome mis-alignment. |
1001753-24-7 |
DC4153 |
Irinotecan hydrochloride trihydrate
Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. |
136572-09-3 |
DC8934 |
Irinotecan
Featured
Irinotecan(CPT-11) prevents DNA from unwinding by inhibition of topoisomerase 1. |
97682-44-5 |
DC7431 |
ISRIB
Featured
ISRIB (trans-isomer), the trans-isomer of ISRIB, is a potent and selective PERK inhibitor with IC50 of 5 nM. |
1597403-47-8 |
DC7178 |
JNJ-7706621
Featured
JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1. |
443797-96-4 |
DC11080 |
JPI-289
JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM. |
1449233-60-6 |
DC7169 |
JW55
Featured
JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively. |
664993-53-7 |
DC7774 |
Ripasudil(K-115)
Featured
K-115, an isoquinolinesulfonamide compound, is a highly selective and potent (IC50 = 31 nM) Rho-kinase inhibitor; is in Phase II clinical development in patients with POAG or ocular hypertension. |
887375-67-9 |
DC7871 |
KCL-440
KCL-440 is a a new poly(ADP-ribose) polymerase- PARP inhibitor. |
651029-09-3 |
DC5093 |
NSC-664704(Kenpaullone)
Featured
Kenpaullone is an ATP-competitive inhibitor of several cyclin-dependent kinases (CDKs) as well as glycogen synthase kinase 3β (GSK3β). |
142273-20-9 |
DC3113 |
KU-0060648
Featured
KU 0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. |
881375-00-4 |
DC1067 |
KU-55933
Featured
KU-55933 is a potent and specific ATM inhibitor with IC50 and Ki of 13 nM and 2.2 nM, respectively. |
587871-26-9 |
DC7448 |
KU-60019
Featured
KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM. |
925701-46-8 |
DC9394 |
LDC000067
Featured
LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7. |
1073485-20-7 |
DC10143 |
LDC-4297
Featured
LDC4297 is a novel CDK7 inhibitor. |
1453834-21-3 |
DC9773 |
LEE011 hydrochloride
Featured
LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1211443-80-9 |
DC7453 |
Ribociclib (LEE011)
Featured
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1211441-98-3 |
DC9774 |
LEE011 succinate
Featured
LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1374639-75-4 |
DC7103 |
LY2603618(IC-83)
Featured
LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
911222-45-2 |